Loading company…
NovoBind develops single-domain antibody treatments for livestock health and food safety applications.
NovoBind develops single-domain antibodies, called NBXs, that target pathogens affecting food production and food safety. The products can be incorporated into feed, feed additives, water, or egg-based applications. Based in Vancouver, Canada, the company was founded in 2012. In April 2023, it received USD 0.030 million in grant funding from Invest Nova Scotia.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign inWork at Novobind Livestock Therapeutics Inc.? This is my company